Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab vs Mitomycin in Limited-stage Anal Squamous Cell Carcinoma
NCT07692152Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in anal squamous cell carcinoma (SCCA), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Mar 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT07692152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692152.